Cash from Operations (Quarterly) Chart

Historical Cash from Operations (Quarterly) Data

View and export this data back to 2015. Start Trial.
Date Value
September 30, 2026 -19.67M
June 30, 2026 -25.84M
March 31, 2026 -33.42M
December 31, 2025 -30.26M
September 30, 2025 -31.05M
June 30, 2025 -33.26M
March 31, 2025 -37.90M
December 31, 2024 -14.53M
September 30, 2024 -27.97M
June 30, 2024 -31.58M
March 31, 2024 58.77M
December 31, 2023 -23.76M
September 30, 2023 -21.05M
June 30, 2023 -0.835M
March 31, 2023 123.56M
December 31, 2022 -12.24M
September 30, 2022 -16.20M
June 30, 2022 -18.49M
March 31, 2022 34.43M
December 31, 2021 11.20M
September 30, 2021 -20.71M
June 30, 2021 -22.72M
March 31, 2021 -21.29M
December 31, 2020 -21.98M
Date Value
September 30, 2020 -24.74M
June 30, 2020 -21.20M
March 31, 2020 -28.80M
December 31, 2019 -23.36M
September 30, 2019 -21.58M
June 30, 2019 -31.56M
March 31, 2019 125.16M
December 31, 2018 -24.35M
September 30, 2018 -17.65M
June 30, 2018 -22.50M
March 31, 2018 48.61M
December 31, 2017 -14.83M
September 30, 2017 -15.89M
June 30, 2017 -16.34M
March 31, 2017 -14.29M
December 31, 2016 -13.09M
September 30, 2016 -10.19M
June 30, 2016 -9.714M
March 31, 2016 -9.487M
December 31, 2015 -9.557M
September 30, 2015 -6.75M
June 30, 2015 -6.982M
March 31, 2015 64.59M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Quarterly) Range, Past 5 Years

View Cash from Operations (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Quarterly) Benchmarks

View Cash from Operations (Quarterly) Benchmarks
Start Trial
Lineage Cell Therapeutics, Inc. -5.62M
Armata Pharmaceuticals, Inc. -5.516M
Black Diamond Therapeutics, Inc. -8.338M
Invivyd, Inc. -32.11M
Elicio Therapeutics, Inc. -10.36M